Stephen Willey joined the Stifel Nicolaus Research Team in connection with Stifel's acquisition of Thomas Weisel Partners LLC in July of 2010. Willey is a Director and follows the Biotechnology industry. Previously, he was a research scientist with ImClone Systems, where he worked in oncology drug discovery and pre-clinical drug development. Before that, Willey was a research associate at Mount Sinai School of Medicine, where he worked in both oncology and stem cell biology. He received a Bachelor's of Science degree from the University of New Hampshire, an Master's degree from the University of Rhode Island, and an Masters of Business Administration from New York University.